09 August 2017
Visiongain has launched a new pharma report The Next Generation Sequencing Market Forecast 2017-2027: Revenue Prospects by Application (Drug Discovery, Genetic Screening, Diagnostics, Personalized Medicine, Agriculture And Animal Research, Infectious Diseases, Others) Technology (Whole-Genome Sequencing, Targeted Re-Sequencing, Exome Sequencing, RNA Seq, Chip Seq, De Novo Sequencing, Methyl Seq, Others), Products (Instruments, Reagents & Consumables, Services), End User (Hospital & Healthcare Institution, Academics, Biotechnology, Pharmaceutical, Others) and Geography
Next-Generation Sequencing (NGS), also known as high-throughput sequencing, can be defined as a process used to sequence DNA strands in parallel and substantially minimize the need for fragment cloning which are used in methods such as Sanger sequencing. NGS is a powerful platform that has enabled the sequencing of millions of DNA molecules whilst simultaneously significantly reducing the cost. With the use of NGS an entire human genome can be sequenced in a day. NGS can be used to sequence entire genomes or constrained to specific areas of interest, including all 22 000 coding genes (a whole exome) or small numbers of individual genes. The data output of NGS has out placed Moore’s Law more than doubling each year.
The development of NGS technologies over the past few years have made large-scale projects such as the Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC) feasible. The technique has provided multi-platform data for thousands of tumours from a variety of cancer types and subtypes as well as integrative analyses of genomic, transcriptomic and epigenomic data, thereby increasing our understanding of cancer biology.
The lead Visiongain report analyst for this report commented; “The market for next generation sequencing is mainly driven by factors such as technological advancements in sequencing platforms, increasing applications of next generation sequencing, growing number of partnerships and collaborations, increasing adoption of next generation sequencing technologies among research laboratories and academic institutes. The application of next generation sequencing in a diverse range of medical conditions will provide new growth opportunities to key players in the next generation sequencing market.”
The Next Generation Sequencing market is highly competitive with many different players entering the market. The report discusses selected leading companies in the market. Notable companies in the global next generation sequencing market include Illumina, Inc., Thermo Fisher Scientific Inc., Pacific Biosciences of California, Inc., Qiagen N.V., Beijing Genomics Institute, Perkinelmer, Inc., F. Hoffmann-La Roche AG, Agilent Technologies, Inc., Gatc Biotech AG, Oxford Nanopore Technologies, Ltd., Macrogen, Inc. and Eurofins Scientific.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The Macular Degeneration (AMD) and Other Retinal Diseases Drugs market was valued at US$25.29 billion in 2021 and is projected to grow at a CAGR of 7.87% during the forecast period 2022-2032.
25 November 2022
Pharmaceutical Contract Manufacturing Organisations (CMOs) market is projected to grow at a CAGR of 6.9% by 2032.
25 November 2022
The Dermatology CROs market was valued at US$ 5,154.8 million in 2021 and is projected to grow at a CAGR of 8.7% during the forecast period 2022-2032.
23 November 2022
The Direct-to-Patient market was valued at US$38,651 million in 2021 and is projected to grow at a CAGR of 6.1% during the forecast period 2022-2032.